Atossa Therapeutics
ATOS
83 hedge funds and large institutions have $45.4M invested in Atossa Therapeutics in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 35 reducing their positions, and 19 closing their positions.
0.18% less ownership
Funds ownership: 2.07% → 1.89% (-0.18%)
9% less funds holding
Funds holding: 91 → 83 (-8)
11% less call options, than puts
Call options by funds: $2.57M | Put options by funds: $2.87M
28% less capital invested
Capital invested by funds: $63.3M → $45.4M (-$17.9M)
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
57% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.26M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$659K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$490K |
| 4 |
State Street
Boston,
Massachusetts
|
+$123K |
| 5 |
Franklin Resources
San Mateo,
California
|
+$96.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$2.46M |
| 2 |
Two Sigma Advisers
New York
|
-$1.24M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.08M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$461K |
| 5 |
D.E. Shaw & Co
New York
|
-$386K |
ATOS Hedge Fund Activity: Q1 2022 in Review
83 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2022, worth a combined $45.4M — down 28% from $63.3M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ATOS and 13 opened new positions — a net loss of 6 holders — while 35 trimmed existing stakes and 15 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.26M. The largest seller was Two Sigma Investments, cutting an estimated $2.46M.
- 83 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2022, down from 91 in Q4 2021.
- Funds reported $45.4M of Atossa Therapeutics stock for Q1 2022, down 28% quarter-over-quarter.
- 13 funds opened new Atossa Therapeutics positions in Q1 2022 and 19 closed out, a net change of -6 holders.
- The largest Atossa Therapeutics buyer in Q1 2022 was Renaissance Technologies, an estimated $1.26M added.
- The largest Atossa Therapeutics seller in Q1 2022 was Two Sigma Investments, an estimated $2.46M sold.
Based on aggregated 13F filings for Q1 2022.